7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
CAS: 2886-65-9
Ref. 3D-FC26451
1g | 166,00 € | ||
2g | 247,00 € | ||
5g | 460,00 € | ||
10g | 652,00 € | ||
500mg | 113,00 € |
Informação sobre produto
- 5-(2-Fluorophenyl)-1,3-dihydro-7-chloro-2H-1,4-benzodiazepin-2-oneNorfludiazepamDesalkylflurazepam
- 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-
- 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-
- 5-(2-Fluorophenyl)-7-Chloro-1,4-Benzodiazepin-2-One
- 7-Chloro-1,3-dihydro-5-(2′-fluorophenyl)-2H-1,4-benzodiazapin-2-one
- 7-Chloro-5-(2-Fluoro-Phenyl)-1,3-Dihydro-2H-1,4-Benzodiazepin-2-One
- 7-Chloro-5-(o-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
- 7-Chloro-5-(o-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one
- 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
- Cm 7116
- Ver mais sinónimos
- Dealkylflurazepam
- Desalkylflurazepam
- Descarbethoxyloflazepate
- N-1-Desalkylflurazepam
- N-Desalkyl-2-oxoquazepam
- N-Desalkylflutoprazepam
- Norflurazepam
- Norflutoprazepam
- Ro 5-3367
- Sch 17514
7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one is a GABA receptor antagonist that is used in the treatment of anxiety. It is an analogue of cinolazepam, which has been shown to inhibit the binding of gamma aminobutyric acid (GABA) to its receptors in human serum and urine samples. Cinolazepam was found to be more potent than 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4 benzodiazepin 2 one in blocking the binding of GABA to its receptor. This drug has also been tested on geriatric patients with high levels of anxiety and found to be well tolerated.
Propriedades químicas
Consulta técnica sobre: 3D-FC26451 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.